Resultats de la cerca - Ursula A. Matulonis

Refinar resultats
  1. 1
    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential per Tarra Evans, Ursula A. Matulonis

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? per Ursula A. Matulonis, Bradley J. Monk

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  3. 3
    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies per Elizabeth K. Lee, Ursula A. Matulonis

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations per Jennifer Veneris, Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers per Elizabeth K. Lee, David L. Kolin, Ursula A. Matulonis, Britt Erickson

    Publicat 2025
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials per Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies per Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  8. 8
    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer per S. Percy Ivy, Joyce F. Liu, Jung‐Min Lee, Ursula A. Matulonis, Elise C. Kohn

    Publicat 2016
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines

    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines per Brian J. Druker, Keiko Okuda, Ursula A. Matulonis, Ravi Salgia, Thomas M. Roberts, JD Griffin

    Publicat 1992
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor per Emily Robinson, Ursula A. Matulonis, Percy Ivy, Suzanne Berlin, Karin Tyburski, Richard T. Penson, Benjamin D. Humphreys

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Ovarian cancer

    Ovarian cancer per Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield, Brooke E. Howitt, Jalid Sehouli, Beth Y. Karlan

    Publicat 2016
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. per Ursula A. Matulonis, Chrysoula Dosiou, GJ Freeman, Christine Lamont, Peter Mauch, L M Nadler, James D. Griffin

    Publicat 1996
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma

    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma per Elizabeth H. Stover, Colleen M. Feltmate, Ross S. Berkowitz, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health per Alexi A. Wright, Nancy L. Keating, Tracy A. Balboni, Ursula A. Matulonis, Susan D. Block, Holly G. Prigerson

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study

    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study per Melissa A. Merritt, Megan S. Rice, Mollie E. Barnard, Susan E. Hankinson, Ursula A. Matulonis, Elizabeth M. Poole, Shelley S. Tworoger

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks per Kun‐Hsing Yu, Vincent J. Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine per Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O’Malley, Ursula A. Matulonis, Gottfried E. Konecny

    Publicat 2023
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  18. 18
    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer

    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer per Michelle Samora, José Eduardo Levi, Sergio Nicolau, Edvane De Domenico, Ursula A. Matulonis, Audrey Tieko Tsunoda, Pâmela Perez Leite, Rafael Schmerling

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance

    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance per Raphaël Ceccaldi, Kevin W. O’Connor, Kent W. Mouw, Adam Y. Li, Ursula A. Matulonis, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells per Young Eun Choi, Chiara Battelli, Jacqueline Watson, Joyce F. Liu, Jennifer Curtis, Alexander Morse, Ursula A. Matulonis, Dipanjan Chowdhury, Panagiotis A. Konstantinopoulos

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: